 Brendan Crawford
Concepts (105)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrotic Syndrome | 3 | 2017 | 34 | 1.130 |
Why?
| | Pseudohypoaldosteronism | 1 | 2024 | 8 | 0.880 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2024 | 12 | 0.880 |
Why?
| | Shiga-Toxigenic Escherichia coli | 1 | 2023 | 3 | 0.820 |
Why?
| | Escherichia coli Infections | 1 | 2023 | 28 | 0.810 |
Why?
| | Kidney Transplantation | 1 | 2023 | 196 | 0.700 |
Why?
| | Kidney Diseases | 1 | 2023 | 229 | 0.690 |
Why?
| | Alleles | 2 | 2016 | 277 | 0.600 |
Why?
| | Nephrosis, Lipoid | 1 | 2017 | 7 | 0.540 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 201 | 0.270 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2006 | 14 | 0.260 |
Why?
| | Genetic Variation | 2 | 2017 | 224 | 0.240 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 174 | 0.230 |
Why?
| | Child | 7 | 2023 | 7147 | 0.230 |
Why?
| | Humans | 16 | 2024 | 52114 | 0.230 |
Why?
| | Histones | 1 | 2006 | 316 | 0.220 |
Why?
| | Renal Dialysis | 2 | 2022 | 190 | 0.220 |
Why?
| | Complement Pathway, Alternative | 1 | 2023 | 4 | 0.210 |
Why?
| | Gene Deletion | 1 | 2024 | 274 | 0.200 |
Why?
| | Constipation | 1 | 2023 | 37 | 0.200 |
Why?
| | Nephrectomy | 1 | 2023 | 81 | 0.200 |
Why?
| | Diarrhea | 1 | 2023 | 95 | 0.200 |
Why?
| | Hypercalcemia | 1 | 2022 | 34 | 0.190 |
Why?
| | Renal Insufficiency | 1 | 2023 | 110 | 0.190 |
Why?
| | Catheter-Related Infections | 1 | 2022 | 49 | 0.190 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2022 | 37 | 0.190 |
Why?
| | Infant, Newborn, Diseases | 1 | 2022 | 57 | 0.180 |
Why?
| | Infant, Newborn | 3 | 2024 | 2859 | 0.180 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2021 | 14 | 0.170 |
Why?
| | Kidney | 1 | 2023 | 713 | 0.150 |
Why?
| | Heart Diseases | 1 | 2021 | 220 | 0.140 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2017 | 20 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2022 | 499 | 0.130 |
Why?
| | Phenotype | 2 | 2017 | 794 | 0.130 |
Why?
| | Heart Failure | 1 | 2022 | 565 | 0.130 |
Why?
| | Gene Frequency | 1 | 2016 | 98 | 0.130 |
Why?
| | Cohort Studies | 2 | 2021 | 1541 | 0.130 |
Why?
| | Microfluidics | 1 | 2016 | 7 | 0.130 |
Why?
| | Age of Onset | 1 | 2016 | 109 | 0.130 |
Why?
| | Infant Care | 1 | 2016 | 19 | 0.120 |
Why?
| | Reference Values | 1 | 2016 | 313 | 0.120 |
Why?
| | Mutation, Missense | 1 | 2016 | 108 | 0.120 |
Why?
| | Genetics, Population | 1 | 2015 | 13 | 0.120 |
Why?
| | Premature Birth | 1 | 2017 | 150 | 0.120 |
Why?
| | Risk | 1 | 2016 | 312 | 0.120 |
Why?
| | Young Adult | 4 | 2017 | 4307 | 0.110 |
Why?
| | Health Education | 1 | 2016 | 156 | 0.110 |
Why?
| | Child, Preschool | 3 | 2021 | 4001 | 0.110 |
Why?
| | Female | 5 | 2024 | 28055 | 0.110 |
Why?
| | Software | 1 | 2016 | 280 | 0.110 |
Why?
| | Adult | 6 | 2022 | 14095 | 0.100 |
Why?
| | Patient Discharge | 1 | 2016 | 322 | 0.100 |
Why?
| | Mothers | 1 | 2016 | 266 | 0.100 |
Why?
| | Treatment Outcome | 1 | 2023 | 5456 | 0.100 |
Why?
| | Male | 3 | 2024 | 26652 | 0.100 |
Why?
| | Adolescent | 3 | 2016 | 6681 | 0.080 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 10 | 0.080 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2009 | 20 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2009 | 60 | 0.080 |
Why?
| | Myeloproliferative Disorders | 1 | 2009 | 31 | 0.080 |
Why?
| | Piperazines | 1 | 2009 | 125 | 0.070 |
Why?
| | Pyrimidines | 1 | 2009 | 198 | 0.070 |
Why?
| | Middle Aged | 3 | 2016 | 13028 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2009 | 424 | 0.060 |
Why?
| | Methyltransferases | 1 | 2006 | 27 | 0.060 |
Why?
| | Methylation | 1 | 2006 | 126 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2006 | 373 | 0.060 |
Why?
| | Prospective Studies | 2 | 2022 | 2424 | 0.050 |
Why?
| | Infant | 2 | 2022 | 3660 | 0.050 |
Why?
| | Dialysis | 1 | 2022 | 6 | 0.050 |
Why?
| | Catheters | 1 | 2022 | 34 | 0.050 |
Why?
| | Genotype | 2 | 2017 | 563 | 0.050 |
Why?
| | Renal Replacement Therapy | 1 | 2023 | 49 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1214 | 0.040 |
Why?
| | North America | 1 | 2021 | 75 | 0.040 |
Why?
| | Ultrasonography | 1 | 2022 | 420 | 0.040 |
Why?
| | Caregivers | 1 | 2023 | 236 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2022 | 6610 | 0.040 |
Why?
| | Infant, Premature | 1 | 2022 | 327 | 0.040 |
Why?
| | Heart Arrest | 1 | 2021 | 135 | 0.040 |
Why?
| | Lung | 1 | 2022 | 488 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2021 | 451 | 0.040 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 300 | 0.030 |
Why?
| | Hospitalization | 1 | 2022 | 739 | 0.030 |
Why?
| | Quality of Life | 1 | 2023 | 878 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 184 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 26 | 0.030 |
Why?
| | Parity | 1 | 2016 | 53 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 219 | 0.030 |
Why?
| | Animals | 2 | 2009 | 13332 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 460 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2017 | 1193 | 0.030 |
Why?
| | Pilot Projects | 1 | 2016 | 712 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2009 | 22 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 50 | 0.020 |
Why?
| | Risk Factors | 1 | 2017 | 3922 | 0.020 |
Why?
| | Spleen | 1 | 2009 | 169 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3382 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2009 | 560 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 188 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 324 | 0.020 |
Why?
| | United States | 1 | 2017 | 5168 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2009 | 1467 | 0.010 |
Why?
| | Aged | 1 | 2015 | 10142 | 0.010 |
Why?
| | Mice | 1 | 2009 | 5877 | 0.010 |
Why?
|
|
Crawford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|